XTAL Pi Makes Strategic Investment in Mirxes to Unlock New Possibilities in AI-Powered Cancer Early Detection and Precision Therapy

Just now,AI Pharmaceutical LeaderReleased by XtalPiA Bombshell Announcement，Ignite the Biotech Investment CircleHot Discussion！

XtalPi Announces Participation as a Strategic Investor inMirxes（Miread）New Share Placement, and will jointly establish a joint venture in China and Singapore to jointly launch the "Gradual Elimination of Gastric Cancer Plan".

This not only provides an important footnote to the mystery of Mirxes' recent massive fundraising round of 710 million Hong Kong dollars, but also marks a qualitative leap in its strategic blueprint – from a leading early screening testing company, it is expected to gradually evolve into an ecosystem platform builder that controls the entire chain of "AI early screening + precision treatment" in the future.

（One）Three Steps to New Heights: A“Long-planned”Construction of the Ecological Closed Loop

This cooperation was not achieved overnight but followed a precise three-step process from "anchoring" to "investment" and then to "integration," with each step landing on a critical node for value amplification. The construction of the entire alliance was clearly divided into three phases, advancing layer by layer:

The first stage isStrategic AnchoringAs early as December 2025, XtalPi and Mirxes had signed a Memorandum of Understanding (MoU). Leveraging the 100,000-level clinical and real-world data accumulated by Mirxes over the past 12 years across multiple Asia-Pacific countries, the two parties are jointly building an AI-powered "diagnosis-treatment integration" platform. This marks the transition of their shared vision from a blueprint on paper to the operational stage, establishing the development goal of extending from "early screening" to "treatment."

The second phase isCapital BindingIn this round of placement worth nearly HK$710 million, XtalPi strategically invested as a strategic investor. This is by no means a simple financial investment but a deep binding of interests through capital. XtalPi's investment at a price higher than the IPO issue price strongly endorses MiRXES' technology and market position, elevating the partnership from a business level to a strategic shareholder level.

The third phase isEntity Integration。With the capital in place, the two parties quickly joined forces with SIGNET, an innovative drug research and development company, to establish a joint venture, officially launching the "Gradual Elimination of Gastric Cancer Plan." This step transforms the initial vision and capital investment into a commercial project with a clear goal, defined path, and tangible entity. SIGNET’s pipeline for the world's first targeted drug for diffuse gastric cancer fills the final and most crucial link in "treatment."

This clear path from "business cooperation" to "capital binding" and then to "entity operation" indicates that this alliance is a well-thought-out, step-by-step strategic advancement. XtalPi's entry provides MiRXES with top-tier AI computing power and drug R&D resources necessary for upgrading from "technology leadership" to "ecosystem leadership."

（Two）Value Reevaluation: Mirxes' "Second Growth Curve" Officially Launched

This collaboration will completely reconstruct the valuation logic of Miread from three dimensions.

First, it isThe Leap of the Track。The core product of Mirxes, "Mi Xiao Wei," as the "first certificate" for early gastric cancer screening in China, naturally occupies a leading position in the billion-dollar early screening market. However, through the alliance with XtalPi and Signet Therapeutics, Mirxes has achieved a historical breakthrough in its business boundaries, extending vertically from the single "screening" link to "diagnosis," "medication guidance," and even "innovative drug development." This allows it to enter the much larger billion-dollar precision treatment market. The core of its business model has been upgraded from providing "testing services" to offering "comprehensive solutions from detection to treatment," significantly broadening its potential.

Secondly, it isModel Upgrade. Mirxes' previously undervalued asset is its over a decade of deep cultivation in the Asian market.Exclusive, Extensive, High-Quality Real-World Cancer Multi-Omics DatabasePreviously, the value of these assets had not been fully unleashed. Now, driven by XtalPi's AI engine, this core asset has been fully activated: it can not only optimize the accuracy of its own early screening algorithms but also be transformed into "high-dimensional fuel" to drive AI in discovering entirely new drug targets, directly empowering Signet Therapeutics' pipeline development. This means that Mirei's future profit model will become more diversified: on top of stable testing revenue, additional layers will be added.Data value authorization, milestone revenue from joint R&D, and sales sharing after the future innovative drug is marketed. Its value ceiling has been completely opened.

Finally, it isEstablishment of Ecological NicheIn the future of the healthcare industry, the greatest value will belong to platform-type hubs that can connect key resources and establish industry rules. Through this deep integration, Mirxes has precisely positioned itself."Asia Cancer Real-World Data Portal"This unique and competitively positioned niche connects at the upper end to the leading AI pharmaceutical brain (XtalPi) and at the lower end to cutting-edge innovative drug transformation entities (Signet Therapeutics), while firmly holding the clinical entry point and core data foundation. This kind of “Data-Algorithm-Drug-Clinical"Once the strong closed loop succeeds in operation, it will generate a powerful network effect and ecosystem stickiness, transforming Mirxes from a potentially replaceable 'track player' into a 'platform core' that gradually defines industry collaboration models.

Conclusion: The traffic light signal is clear.

XtalPi, as a strategic investor, has taken a premium stake and co-founded a physical joint venture. The intensity and depth of this series of actions far exceed ordinary business cooperation. This represents a high level of recognition by industrial capital of Miread's core value and also clearly answers the market's previous core concerns: the nearly HK$2 billion financing is not only for market expansion but ultimately aims toBuild a new ecosystem for cancer diagnosis and treatment with exclusive data as the cornerstone, AI as the engine, and solving major diseases as the goal.。

For investors, the framework for evaluating Mirxes needs to be updated:

· In the short termThe commercial scaling of the early gastric cancer screening product "Mi Xiao Wei" in the Chinese market remains the ballast of its performance.

· Medium-termThe integration progress with XtalPi's AI platform, the discovery of new biomarkers, and the advancement of multi-cancer pipelines will be important value catalysts.

· In the long termThe operational effectiveness of the joint venture, the actual changes brought by the "Gastric Cancer Elimination Plan" to clinical practice, and whether the entire ecosystem platform can continuously generate synergistic revenue and profits will ultimately determine its long-term value potential.

· Throughout the entire process, the nearly HK$2 billion in massive financing and XtalPi's strategic investment have been the "fuel" and "catalyst" driving all the aforementioned steps from blueprint to reality.This funding not only provides ample ammunition for "Mi Xiao Wei's" market offensive but also serves as the financial foundation supporting its mid-to-long-term strategies, such as the AI-integrated R&D with XtalPi and the expansion of multi-cancer pipelines. It also fortifies the capital moat for building an irreplicable ecosystem loop.

In summary, Mirxes' "traffic light signal" hasIncreasingly Clear, but this lamp no longer illuminates an isolated track,But a new multi-party collaborative ecosystem for cancer diagnosis and treatment.。The resilience of its stock price in the midst of volatility is precisely the early sign that the market has begun to focus on this scarcity value leap—from "technical tool" to "ecological platform"—and is pricing it with foresight.